Sunday, March 31, 2013

Proposed criteria for Refractory Migraine

A) Primary diagnosis ICHD II Migraine or Chronic Migraine
B) Significant interference with QOL despite
• modification of triggers, lifestyle factors
• adequate trials of acute and preventive medicines

Preventive medicines (at least 3 of 4)
1 Beta Blocker
2 Anticonvulsant
3 Tricyclics
4 Calcium channel blocker

Abortive medicines (all)
1 Both a triptan and DHE intranasal or injectable
2 Either a non steroidal anti-inflammatory drug or combination analgesics

Adequate trial  - 2 months/ less if stopped because of adverse effects, with dose being optimal/ maximum tolerated

Modifiers +/-
1 With or without medication overuse
2 With or without significant disability (MIDAS score >11)

Criteria for refractory migraine (proposed)


Tuesday, March 19, 2013

Revised Criteria Alzheimer's (Du Bois)

Probable AD: A plus one or more supportive features B, C, D, or E

Core diagnostic criteria

A. Presence of an early and significant episodic memory impairment that includes the following features:

1. Gradual and progressive change in memory function reported by patients or informants over more than 6 months
2. Objective evidence of significantly impaired episodic memory on testing: this generally consists of recall deficit that does not improve significantly or does not normalise with cueing or recognition testing and after effective encoding of information has been previously controlled.

The episodic memory impairment can be isolated or associated with other cognitive changes at the onset of AD or as AD advances
Supportive features

B. Presence of medial temporal lobe atrophy

•  Volume loss of hippocampi, entorhinal cortex, amygdala evidenced on MRI with qualitative ratings using visual scoring (referenced to well characterised population with age norms) or quantitative volumetry of regions of interest (referenced to well characterised population with age norms)

C. Abnormal cerebrospinal fluid biomarker

• Low amyloid β1–42 concentrations, increased total tau concentrations, or increased phospho-tau concentrations, or combinations of the three
• Other well validated markers to be discovered in the future

D. Specific pattern on functional neuroimaging with PET

• Reduced glucose metabolism in bilateral temporal parietal regions
• Other well validated ligands, including those that foreseeably will emerge such as Pittsburg compound B or FDDNP

E. Proven AD autosomal dominant mutation within the immediate family

Exclusion criteria

History

• Sudden onset 
• Early occurrence of the following symptoms: gait disturbances, seizures, behavioural changes

Clinical features

• Focal neurological features including hemiparesis, sensory loss, visual field deficits
• Early extrapyramidal signs

Other medical disorders severe enough to account for memory and related symptoms

• Non-AD dementia 
• Major depression 
• Cerebrovascular disease 
• Toxic and metabolic abnormalities, all of which may require specific investigations 
• MRI FLAIR or T2 signal abnormalities in the medial temporal lobe that are consistent with infectious or vascular insults

Criteria for definite AD

AD is considered definite if the following are present:

• Both clinical and histopathological (brain biopsy or autopsy) evidence of the disease, as required by the NIA-Reagan criteria for the post-mortem diagnosis of AD; criteria must both be present
• Both clinical and genetic evidence (mutation on chromosome 1, 14, or 21) of AD; criteria must both be present

Criteria for Sjogren's syndrome

I. Ocular Symptoms (at least one)

Dry eyes >3 months?
Foreign body sensation in the eyes?
Use of artificial tears >3x per day?

II. Oral Symptoms (at least one)

Dry mouth >3 months?
Recurrent or persistently swollen salivary glands?
Need liquids to swallow dry foods?

III. Ocular Signs (at least one)

Schirmer's test, (without anesthesia) ≤5 mm/5 minutes
Positive vital dye staining (van Bijsterveld ≥4)

IV. Histopathology 

Lip biopsy showing focal lymphocytic sialoadenitis
(focus score ≥1 per 4 mm2)

V. Oral Signs (at least one)

Unstimulated whole salivary flow (≤1.5 mL in 15 minutes)
Abnormal parotid sialography3
Abnormal salivary scintigraphy4

VI. Autoantibodies (at least one)

Anti-SSA (Ro) or Anti-SSB (La)

For a primary Sjögren’s diagnosis:
a. Any 4 of the 6 criteria, must include either item IV (Histopathology) or VI (Autoantibodies)
b. Any 3 of the 4 objective criteria (III, IV, V, VI)

For a secondary Sjögren’s diagnosis:
In patients with another well-defined major connective tissue disease, the presence of one symptom (I or II) plus 2 of the 3 objective criteria (III, IV and V) is indicative of secondary SS.

Exclusion Criteria

Past head and neck radiation treatment
Hepatitis C infection
Acquired immunodeficiency syndrome (AIDS)
Pre-existing lymphoma
Sarcoidosis
Graft versus host disease
Current use of anticholinergic drugs

Saturday, March 16, 2013

My present stand on DBS in India

If I receive a mail enquiry from someone I do not know, I give them a list of places where DBS is done. If someone I know asks, I tell them pros and cons and give a list mentioning where the largest numbers are from. I specifically mention the purely symptomatic nature of therapy, the requirement for intensive follow up and the problems of DBS/ dopaminergic dose reduction on cognition and behavior. However if it is a relative who asks, I would not recommend DBS if they have to sell land or leave their job and relocate. I tell them that optimal medical and physical therapy is still very much an option; that most available literature recommending DBS is of short duration (6 to 24 months) or inadequate numbers if longer duration, implying that the long term benefits are being extrapolated. (I don't mention conflict of interest due to involvement of the company manufacturing the device.)

Tuesday, March 5, 2013

Electrical injury and non progressive motor syndromes

J Neurol Neurosurg Psychiatry. 2007 May;78(5):450-3. Epub 2006 Nov 10.
Electrical injury and amyotrophic lateral sclerosis: a systematic review of the literature.
Abhinav K, Al-Chalabi A, Hortobagyi T, Leigh PN.
Queen Elizabeth Hospital, London, UK.

Electrical injury may act as a potential precipitating or risk factor for amyotrophic lateral sclerosis (ALS). A systematic review of the literature was undertaken to assess the relationship between electrical injury and the development of ALS. Information for the review was obtained using five medical databases, and from manual searching of individual papers. Patients presenting with a neurological syndrome after electrical injury, including lightning, were included and classified into four categories: ALS; progressive upper motor neurone (UMN) syndrome; progressive lower motor neurone (LMN) syndrome; and non-progressive syndrome. Linear regression and chi2 testing were used for analysis of the data. 96 individuals, comprising 44 with ALS, 1 with a progressive UMN syndrome, 7 with a progressive LMN syndrome and 44 with a non-progressive syndrome, were identified from 31 papers with publication dates between 1906 and 2002. The median interval between electrical injury and disease onset was 2.25 years for all progressive syndromes and just over 1 week for the non-progressive syndrome. The more severe the shock (excluding lightning), the
more likely individuals were to have a non-progressive motor syndrome. A non-progressive spinal cord syndrome is associated with more severe electrical injury. Overall, the evidence reviewed does not support a causal relationship between ALS and electric shock.

PMCID: PMC2117843
PMID: 17098839 

The flushing patient

Neurology and Psychiatry


C Butler, A Z J Zeman. Neurological syndromes which can be mistaken for psychiatric conditions. J Neurol Neurosurg Psychiatry 2005;76:i31-i38.

All illness has both psychological and physical dimensions. This may seem a startling claim, but on reflection it is uncontroversial. Diseases don’t come to doctors, patients do—and the processes by which patients detect, describe, and ponder their symptoms are all eminently psychological. This theoretical point has practical implications. If we adopt a “bio-psycho-social” approach to illness generally, one which recognises the biological, psychological, and social aspects of our lives, we become less likely to neglect the treatable psychological origins of many physical complaints (from globus hystericus to full blown conversion disorder) and the treatable psychological consequences (such as depression and anxiety) of much physical disease.

Friday, December 14, 2012

Spontaneous improvement in NMO? Rare

J Korean Neurol Assoc. 2011 Feb;29(1):52-54. Korean.
Long Spontaneous Remission in Neuromyelitis Optica.
Kang HG, Kim SS, Jeong J, Jo JH, Yi MJ, Lee HS, Park HY, Chang H, Kim YS, Cho KH.
Department of Neurology, Wonkwang University School of Medicine, Iksan, Korea. neurlogy@wonkwang.ac.kr

Abstract
Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system characterized by optic neuritis and longitudinal extensive transverse myelitis. The clinical course can be either polyphasic (relapsing-remitting) or monophasic. The relapsing-remitting course is observed in more than 80% of NMO cases, and relapse generally occurs within 1 year in 60% of patients, and within 3 years in 90%. We report a rare case of long spontaneous remission in untreated NMO.

Spontaneous recovery in ADEM?


J Neurol Neurosurg Psychiatry 2004;75:i22-i28 doi:10.1136/jnnp.2003.034256
INFLAMMATORY/POST-INFECTIOUS ENCEPHALOMYELITIS

L Bennetto, N Scolding
Author Affiliations: Institute of Clinical Neurosciences, Department of Neurology, University of Bristol, Frenchay Hospital, Bristol, UK

Spontaneous recovery is the rule, usually over a course of weeks to months. ADEM tends to have a more severe initial course but much better ultimate recovery than MS. Historically fatal disease was common, with reported mortality rates as high as 30–50% as recently as 1948 in European children with post-vaccination ADEM. The outlook this millennium appears much brighter, with three recent studies encompassing 150 children with ADEM reporting no deaths. One of these studies followed up their 35 cases for a mean 5.8 years and found that the majority completely recovered in a few weeks. Twenty patients had no long term impairment; permanent neurological deficits included motor dysfunction (six patients, severe in three), cognitive impairment (four patients), visual loss (four patients), and behavioural problems (four patients). Epilepsy developed in three patients but persisted in only one with extended follow up. A recent study of 40 adult patients with ADEM reported two mortalities, suggesting that adult ADEM may presently have a slightly worse prognosis than childhood ADEM.

Treatment options

Corticosteroids are widely considered to be an effective first line treatment for ADEM. Intravenous methylprednisolone 1 g daily for at least three days is advised. While expert opinion and several convincing reports support this regimen, the natural history of ADEM of course features spontaneous improvement, and it is difficult therefore to be absolutely certain of its benefits. The recent trend towards improved survival in reported case series of ADEM may, however, reflect increased use of corticosteroids, intravenous methylprednisolone in particular. The rationale for corticosteroid use is their ability to reduce inflammation, decrease oedema, and seal the blood–brain barrier, which should decrease the further influx of active immune cells and humoral factors, contributing to demyelination. In some cases, cessation of steroid treatment has been followed by a relapse, possibly forming the basis of MDEM. As a relapse suggestive of MDEM is most likely shortly after ADEM it would seem prudent to prescribe a 1–2 month oral prednisolone taper.

Plasma exchange is recommended in patients who respond poorly to intravenous corticosteroids. There have also been several reports of impressive responses to plasma exchange; however, some of these have been confounded by the co-administration of corticosteroids and cyclophosphamide. More importantly a randomised, controlled, crossover trial of true versus sham plasma exchange for attacks of severe CNS demyelination resistant to corticosteroid treatment in 22 patients showed that 42% of patients had moderate or greater neurological improvement in the plasma exchange arm compared with just 6% of the patients receiving sham treatment (statistically significant). Although this study only had one patient with ADEM, the other conditions treated under the remit of “severe CNS demyelination”—MS, Marburg variant MS, acute transverse myelitis, neuromyelitis optica—are sufficiently similar and occasionally indistinguishable from ADEM in the acute phase to represent a reasonable rationale for treatment at present. This study used a course of seven plasma exchanges over 14 days, but improvement is frequently observed after the first exchange.

Intravenous immunoglobulin (IVIG) has also been used with success in a few cases of ADEM. While the evidence behind its use in ADEM is probably weaker than that of plasma exchange, there are several neuro-inflammatory conditions where IVIG has a proven effect and is often considered a more convenient alternative to plasma exchange. At present it should be reserved for ADEM that fails to respond to corticosteroid treatment and where plasma exchange is contraindicated or impractical. There have been suggestions based on subtle pathogenetic differences that IVIG may be preferable to plasma exchange in cases of post-vaccination encephalomyelitis, but this is not proven. Intravenous cyclophosphamide has also been used in the past with some apparent success but has not gained widespread recommendation.

In severe cases of ADEM, and particularly acute haemorrhagic leucoencephalomyelitis, cerebral oedema can occur and should be treated with combinations of mannitol and hyperventilation. If these conservative measures fail then more drastic measures such as craniotomy can be considered.

ADEM has been known to relapse into MDEM following routine vaccinations and it would seem sensible to avoid vaccinations (or other immune stimulation) for at least six months following a diagnosis of ADEM.

Article discussing Opercular Syndrome in ADEM

http://pn.bmj.com/content/10/2/109.full

Pract Neurol 2010;10:109-111 doi:10.1136/jnnp.2010.206110
The groom who could not say “I do”

A 25-year-old North American man came to Portugal on honeymoon. The week before, he had developed slowly progressive difficulty with both speaking and swallowing. At his wedding ceremony in the USA 2 days earlier, he had not been able to speak, saying “I do” using gestures, and could barely eat his own wedding cake. He deteriorated further after the wedding and by the following day he was unable to swallow.

Ten days before the onset of these symptoms, he had suffered a flu-like illness that resolved spontaneously over a couple of days. He was previously healthy, not taking any medication and not using any illicit drugs.

On examination, he was calm and alert, capable of following commands and could read and write which facilitated communication. He was anarthric, making only effortful guttural sounds and required nasogastric tube feeding because of severe dysphagia. He had bilateral ptosis and bilateral facial weakness. However, while his voluntary mouth opening was limited, it was normal when he yawned. His palatal movement was reduced but his gag reflex was intact, as was his jaw jerk. He could not cough voluntarily but had a reflex cough. He was unable to protrude or move his tongue from side to side. Ocular movements were normal and he had normal strength in his arms and legs with symmetrical tendon reflexes. He was apyrexial and haemodynamically stable. The rest of his general examination was normal.

FTD ALS overlap

J Mol Neurosci. 2011 Nov;45(3):656-62. doi: 10.1007/s12031-011-9636-x. Epub 2011 Oct 5.

Clinical phenomenology and neuroimaging correlates in ALS-FTD.

Source

Department of Neurology, University of California, San Francisco, 350 Parnassus Avenue, Suite 500, San Francisco, CA 94117, USA. catherine.lomen-hoerth@ucsf.edu

Abstract

The overlap of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) has been well documented in FTD patients with co-morbid motor neuron degeneration and in ALS patients with frontotemporal dysfunction. Up to 15% of FTD patients and 30% of ALS patients experience the overlap syndrome. The syndrome may be difficult to identify since patients often present either to a neuromuscular clinic or a memory disorder's center, each which may have limited expertise in the other specialty. Survival is greatly impacted for both disorders in the co-morbid condition, making identification of this syndrome critical. The clinical characteristics of the overlap syndrome with new diagnostic criteria will be discussed along with screening strategies, including the UCSF Screening battery and clinical neurophysiology techniques. Treatable mimics of this disorder will also be described and management techniques. Neuroimaging findings will be summarized, which show that the frontotemporal impairment in ALS patients lies on a continuum. Identification of the overlap syndrome also provides a unique opportunity to study very early signs of FTD and conversely, very early signs of ALS, to gain greater insight into both disorders.

Wednesday, November 21, 2012

Questions on EEG

  1. What is electricity?
  2. How do we measure it? 
  3. What do we measure when we put an electrode on the scalp?
  4. Obviously there is no movement of electrons across the electrodes, so it must be measuring some sort of a field. What is meant by electric field, how is it different from electromagnetic field and electrostatic field?
From www.physicsclassroom.com

Structure of matter

Not only do electrostatic occurrences permeate the events of everyday life, without the forces associated with static electricity, life as we know it would be impossible. Electrostatic forces - both attractive and repulsive in nature - hold the world of atoms and molecules together in perfect balance. Without this electric force, material things would not exist. Atoms as the building blocks of matter depend upon these forces. And material objects, including us Earthlings, are made of atoms and the acts of standing and walking, touching and feeling, smelling and tasting, and even thinking is the result of electrical phenomenon. Electrostatic forces are foundational to our existence.

Boyle's studies (middle to late 1600s) of gaseous substances promoted the idea that there were different types of atoms known as elements. Dalton (early 1800s) conducted a variety of experiments to show that different elements can combine in fixed ratios of masses to form compounds. Dalton subsequently proposed one of the first theories of atomic behavior that was supported by actual experimental evidence.

English scientist J.J. Thomson's cathode ray experiments (end of the 19th century) led to the discovery of the negatively charged electron and the first ideas of the structure of these indivisible atoms. Thomson proposed the Plum Pudding Model, suggesting that an atom's structure resembles the favorite English dessert - plum pudding. The raisins dispersed amidst the plum pudding are analogous to negatively charged electrons immersed in a sea of positive charge.

Nearly a decade after Thomson, Ernest Rutherford's famous gold foil experiments led to the nuclear model of atomic structure. Rutherford's model suggested that the atom consisted of a densely packed core of positive charge known as the nucleus surrounded by negatively charged electrons. While the nucleus was unique to the Rutherford atom, even more surprising was the proposal that an atom consisted mostly of empty space. Most the mass was packed into the nucleus that was abnormally small compared to the actual size of the atom.

Neils Bohr improved upon Rutherford's nuclear model (1913) by explaining that the electrons were present in orbits outside the nucleus. The electrons were confined to specific orbits of fixed radius, each characterized by their own discrete levels of energy. While electrons could be forced from one orbit to another orbit, it could never occupy the space between orbits.

Bohr's view of quantized energy levels was the precursor to modern quantum mechanical views of the atoms. The mathematical nature of quantum mechanics prohibits a discussion of its details and restricts us to a brief conceptual description of its features. Quantum mechanics suggests that an atom is composed of a variety of subatomic particles. The three main subatomic particles are the proton, electron and neutron. The proton and neutron are the most massive of the three subatomic particles; they are located in the nucleus of the atom, forming the dense core of the atom. The proton is charged positively. The neutron does not possess a charge and is said to be neutral. The protons and neutrons are bound tightly together within the nucleus of the atom. Outside the nucleus are concentric spherical regions of space known as electron shells. The shells are the home of the negatively charged electrons. Each shell is characterized by a distinct energy level. Outer shells have higher energy levels and are characterized as being lower in stability. Electrons in higher energy shells can move down to lower energy shells; this movement is accompanied by the release of energySimilarly, electrons in lower energy shells can be induced to move to the higher energy outer shells by the addition of energy to the atom. If provided sufficient energy, an electron can be removed from an atom and be freed from its attraction to the nucleus.

Summary:

  • All material objects are composed of atoms. There are different kinds of atoms known as elements; these elements can combine to form compounds. Different compounds have distinctly different properties. Material objects are composed of atoms and molecules of these elements and compounds, thus providing different materials with different electrical properties.
  • An atom consists of a nucleus and a vast region of space outside the nucleus. Electrons are present in the region of space outside the nucleus. They are negatively charged and weakly bound to the atom. Electrons are often removed from and added to an atom by normal everyday occurrences. These occurrences are the focus of this Static Electricity unit.
  • The nucleus of the atom contains positively charged protons and neutral neutrons. These protons and neutrons are not removable or perturbable by usual everyday methods. It would require some form of high-energy nuclear occurrence to disturb the nucleus and subsequently dislodge its positively charged protons. These high-energy occurrences are fortunately not an everyday event. One sure truth of this unit is that the protons and neutrons will remain within the nucleus of the atom. Electrostatic phenomenon can never be explained by the movement of protons.
Concepts in Static Electricity

Rubbing two objects against each other brings the electron fields of the atoms in each close to each other. Electron affinity varies amongst molecules. If there is a significant difference in this property between the two objects being rubbed against each other, then electrons will be transferred. This will result in a charge on the surface of both objects. The charge will obviously be of opposite polarity. It will also be equal in magnitude. This is known as the "Law of conservation of charge". A triboelectric series is the order in which objects are arranged according to the degree of electron affinity.

Dorsal digital expansion

Finger extension - DDE - 'Diamond' complex
1) Axis - Extensor digitorum tendon
2) Proximal wing tendon - interossei
3) Distal wing tendon - lumbricals
See Gray's Anatomy 37Ed Fig 5.70 5.71 5.83

Tuesday, November 20, 2012

Immunocompromising conditions

Immunocompromising Conditions (List from eMedicine)
a) Congenital
b) Acquired
c) Iatrogenic / self inflicted

a) Congenital Conditions

These most commonly affect the fetus and newborn. Hemoglobinopathy may be noted.
Syndromes
  • Partial albinism with immunodeficiency (Griscelli) syndrome[2, 3]
  • Hemorrhagic hereditary telangiectasia (Rendu-Osler disease)[4]
  • Immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome
  • Kabuki syndrome
  • Partial albinism, immunodeficiency, and progressive white matter disease (PAID) syndrome
  • Autoimmune polyendocrinopathy syndrome type 1
  • Rubinstein-Taybi syndrome[5]
  • Hermansky-Pudlak-2 syndrome
  • CHARGE syndrome[6]
  • Other dysmorphology or immunodeficiency syndromes
  • Stromal interaction molecule 1 mutation[7]
B-cell defects[8]
  • Antibody deficiency with transcobalamin II deficiency
  • Antibody deficiency with normal or high immunoglobulin (Ig) levels
  • Common variable immunodeficiency
  • IgG heavy-chain deletion
  • IgG subclass deficiency
  • Kappa-chain deficiency
  • Organic cation transporter 2 deficiency
  • Selective IgA deficiency
  • Selective IgM deficiency
  • Selective antipolysaccharide antibody deficiency
  • Transient hypogammaglobulinemia of infancy or early childhood
  • Thymoma with agammaglobulinemia
  • X-linked (Bruton) agammaglobulinemia
  • X-linked hyper-IgM syndrome
  • X-linked hypogammaglobulinemia with growth hormone deficiency
Combined B-cell and T-cell defects
  • Adenosine deaminase deficiency
  • Artemis deficiency
  • Ataxia-telangiectasia syndrome
  • Bare lymphocyte syndrome (major histocompatability complex class I/II deficiency)
  • DOCK8 mutations[9]
  • Interleukin (IL)-2R alpha or gamma deficiency
  • Intestinal lymphangiectasia
  • Janus kinase 3 (JAK3) deficiency
  • Nuclear factor-kappaB essential modifier (NEMO) deficiency (Dupuis-Girod, 2002; Courtois, 2006; Smahi, 2002; Zonana, 2000)
  • Nijmegen breakage syndrome
  • Purine nucleoside phosphorylase deficiency
  • Recombination activation gene (RAG) 1 or 2 deficiency
  • Reticular dysgenesis
  • Swiss-type severe combined immunodeficiency
  • T-cell receptor deficiency
  • X-linked lymphoproliferative syndrome
  • X-linked severe combined immunodeficiency
  • Zeta-associated protein of 70 kDa (ZAP-70) tyrosine kinase deficiency
T-cell defects
  • Biotin-dependent multiple carboxylase deficiency
  • Chronic mucocutaneous candidiasis
  • DiGeorge (velocardiofacial) syndrome
  • Fas defect
  • Nezelof syndrome
  • Short-limbed dwarfism or cartilage-hair hypoplasia
Macrophage, cytokine, and miscellaneous defects
  • Mendelian susceptibility to mycobacterial diseases (MSMD)
    • Interferon-gamma deficiency
    • Interferon-gamma receptor I or II deficiency
    • IL-12 deficiency
    • IL-12 receptor deficiency
    • STAT1 mutations
    • NEMO
    • CYBB
  • IL-1 receptor–associated kinase 4 (IRAK4) deficiency
  • MYD88 deficiency
  • Toll-like receptor 5 mutations
  • Apolipoprotein L-I deficiency
  • UNC-93B deficiency
  • Toll-like receptor 3 mutations
  • TRIF and TRAF3 mutations
  • Plasminogen activator inhibitor-1 4G/4G promoter genotype
  • Anti-interferon-gamma antibodies
  • IL-18 polymorphisms
  • RANTES promoter gene polymorphisms[11]
  • Deficiency of chemokine receptor CCR5[12, 13]
  • Toll-like receptor 4 mutations
  • IL-8 RA (chemokine CXC motif receptor 1 [CXCR1]) mutations
  • CXCR4 mutations (Whim syndrome)
  • STAT 5 mutations
  • NOD2 gene polymorphisms
  • IL-6 polymorphisms
  • Activating killer immunoglobulinlike receptor gene polymorphisms
  • Dectin-1 deficiency
  • CARD9 mutations
  • Polymorphisms in cytokine-inducible SRC homology 2 domain protein (CISH)
  • Polymorphisms in Mal/TIRAP and Interleukin-10
  • Autoantibodies against IL-6[14]
  • Polymorphisms in the IL-8 promoter gene[15]
  • IL-12 receptor deficiency (Vinh, 2011)
Phagocyte deficiency or dysfunction
  • Chediak-Higashi syndrome
  • Chronic granulomatous disease
  • Chronic idiopathic neutropenia
  • Cyclic neutropenia
  • Glycogen storage disease 1b
  • Hyper-IgE/recurrent infection (Job) syndrome (Janus kinase protein tyrosine kinase 2 [Tyk2], signal transducer and activator of transcription [STAT] 3, and STAT 1 mutations)[16]
  • Kostmann syndrome
  • Leukocyte adhesion deficiency (including CD11 or CD18 deficiency)
  • Myeloperoxidase deficiency
  • Neutrophil actin dysfunction
  • Papillon-Lefèvre syndrome
  • Specific granule deficiency
  • Shwachman-Diamond syndrome
Complement deficiencies (Ram, 2010)
  • Mannose-binding lectin (Mannan-binding protein) deficiency[17, 18]
  • Deficiencies of C1q, C1r, C1rs, C4, C2, C3, or C5-9
  • Deficiencies of factor D, factor P, factor I, factor H, or properdin
  • Ficolin-3 (H-ficolin) deficiency[19]
Other conditions
  • Asplenia[20]
  • Ciliary dyskinesia, Kartagener syndrome, and other disorders
  • Galactosemia and other metabolic conditions
  • Lymphedema (congenital)
  • Trisomy 21 and other genetic disorders
  • Other anatomic defects (eg, midline dermal sinus, Mondini defect of the inner ear, fistulae, cysts, duplications, meningeal defects, iron overload, decreased sensation)

b) Acquired Conditions

These conditions may interfere directly with the immune system or may disrupt barrier function.
  • Malnutrition
  • HIV infection: Although human immunodeficiency virus (HIV) infection is a considerable cause of immunodeficiency worldwide, immunocompromise is most likely to result from common problems, including asthma, diabetes, malnutrition, and cancer, among others.
  • Trauma
    • Burns
    • Lacerations and abrasions
  • Medical conditions
    • Collagen vascular
    • GI tract
    • Hematologic or oncologic
    • Hepatic
    • Metabolic
    • Pregnancy
    • Pulmonary, particularly asthma and cystic fibrosis (CF)
    • Renal
    • Skin and mucous membrane
    • Viral infections (eg, cytomegalovirus [CMV] infection,[21] measles)
    • Other anatomic or physiologic problems (eg, fistulae, cysts, obstructions, iron overload, decreased sensation)
  • Acquired asplenia (Ram, 2010)
  • Acquired lymphedema
  • Other conditions that injure or bypass barrier function
    • Parasitic infections
    • Animal and insect bites or scratches

c) Iatrogenic or Self-inflicted Conditions

These conditions may directly interfere with the immune system or may disrupt barrier function.
Use of drugs and/or therapies (eg, radiation therapy), which may interfere with normal flora, decrease gastric acidity and ciliary motility, and be directly immunomodulating[22]
Trauma
  • Injections (eg, insulin injections, intravenous [IV] drug use, others)
  • Operative and other incisions
  • Vascular, osseous, tracheal, gastric, bladder, joint, peritoneal, wound, or ventricular access or drainage devices
  • Internal foreign bodies
  • Major surgery[23]
Treatment
  • For leukemia or lymphoma
  • Bone marrow or stem-cell transplantation
  • Solid organ transplantation (Yin, 2011)
  • Therapy for autoimmune or inflammatory disorders
  • TNF-alpha inhibitors[24]
  • Monoclonal antibodies and related small molecules

Tuesday, November 13, 2012

Wilsons disease with behavioral problems and isolated midbrain lesions

Question - can patients with Wilsons disease present with isolated psychopathic (especially abnormal sexual) behavior?
Yes - see the range of behavioral manifestations in Wilsons http://neuro.psychiatryonline.org/data/Journals/NP/3960/08JNP81.PDFhttp://www.ncbi.nlm.nih.gov/pubmed/7872138 , http://books.google.co.in/books?id=Ag5710EHVpAC&pg=PA23&lpg=PA23&dq=wilsons+disease+substance+abuse&source=bl&ots=63ocZTdPcm&sig=L0H9HbqTcqwIGw-NFNk6j1iklvw&hl=en&sa=X&ei=pCyiUKH4AY7trQf0m4DoBw&ved=0CE4Q6AEwBQ#v=onepage&q=wilsons%20disease%20substance%20abuse&f=false

Question - can patients with Wilsons disease have changes only in midbrain (no changes in putamen / lenticular nuclei)
Yes - see the range of MRI abnormalities in Wilsons http://www.ncbi.nlm.nih.gov/pubmed/17894614http://www.ncbi.nlm.nih.gov/pubmed/20437536http://www.ncbi.nlm.nih.gov/pubmed/16752136

Question - can patients with Wilsons disease have only abnormality of elevated 24 hour urinary copper?
Yes - see the range of biochemical abnormalities and guidelines for diagnosis of Wilsons disease http://www.uptodate.com/contents/tests-used-in-the-diagnosis-of-wilson-diseasehttp://guidelines.gov/content.aspx?id=13004

Wilsons Behavioral Problems 1995 article

http://www.ncbi.nlm.nih.gov/pubmed/7872138

Adv Neurol. 1995;65:171-8.
Psychiatric and behavioral abnormalities in Wilson's disease.
Akil MBrewer GJ.
Department of Psychiatry, University of Pittsburgh, Western Psychiatric Institute and Clinic, Pennsylvania 15213.
From the literature and our experience, a relatively consistent picture of psychiatric and behavioral abnormalities in Wilson's disease emerges. The essential elements of this picture are as follows: 
1. Psychiatric and behavioral abnormalities are frequent manifestations of WD. The estimates range from 30% (18) to 100% (2) of symptomatic patients. As Wilson himself was the first to state in reference to "mental change," "its importance should not be underestimated." 
2. Psychiatric and behavioral abnormalities are often the initial manifestations of WD. Two thirds of our patients first presented with psychiatric symptoms and one third received psychiatric treatment before the diagnosis of WD was made. In the early stages of the disease, when psychiatric and behavioral symptoms predominate, the diagnosis is often missed. Of our 124 patients, WD was diagnosed in only one during this phase. Until the psychiatric presentation of WD is recognized, and the disease is included in the differential diagnosis of psychiatric symptoms, its diagnosis will be missed or delayed. In our patients, and others' (13,15), the delay in diagnosis ranged from 1 to 5 years. Such a delay is particularly tragic as favorable outcome depends upon early discovery. 
3. The most common of the psychiatric and behavioral manifestations of WD include: personality changes such as irritability and low threshold to anger, depression sometimes leading to suicidal ideation and attempts, deteriorating academic and work performance that is present in almost all neurologically affected patients. We (1) have also observed, as did Scheinberg and Sternlieb (2) that WD patients exhibit increased sexual preoccupation and reduced sexual inhibition. Finally, cognitive impairment, psychosis, anxiety, and other psychiatric disorders, although less frequent, also occur. 
4. Some of the psychiatric and behavioral symptoms are reversible with WD-specific therapy, whereas others are not. We are impressed with the frequency with which the behavioral and "cognitive" symptoms are reversed over 1 to 2 years of treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Violence and psychopathic behavior presentation

Neurological and systemic conditions listed on various websites including Crime Times

  1. Temporal lobe/ amygdala lesions - tumors, HSE
  2. Toxins like organophosphates and carbamates
  3. Thyroid disorders
  4. Wilsons disease, Huntington's disease, hyperparathyroidism, vitamin deficiencies, limbic encephalitis, and sleep disorders

Conditions associated with sex offences - Tourette's syndrome (anecdotal response of abnormal sexual behavior to pimozide) and Wilson's disease

Retinal Vasculitis with CNS disease

In a patient with retinal vasculitis, it is useful to know the following:
1) Type of retinal vessels involved - arterioles, venules, capillaries
2) CSF study normal or abnormal
3) MRI Brain normal, vasculitis, white matter changes, ventricular enlargement


Identification of retinal vessels involved 

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855661/
Retinal vasculitis affecting predominantly the veins (phlebitis) has been described in association with Behçet's disease, tuberculosis, sarcoidosis, multiple sclerosis, pars planitis, retinal vasculitis associated with tuberculoprotein hypersensitivity (Eales' disease), human immunodeficiency virus infection (HIV). Retinal arteritis is more commonly seen in acute retinal necrosis, idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) and systemic vasculitides such as SLE, polyarteritis nodosa, and Wegener's granulomatosis, Churg-Strauss syndrome and cryoglobulinemia.

List of causes of retinal vasculitis (Uptodate)


Systemic disorders
Behcet's disease
Granulomatosis with polyangiitis (Wegener's)
Sarcoidosis
Relapsing polychondritis
Systemic lupus erythematosus
Giant cell arteritis
Polyarteritis nodosa
Multiple sclerosis
Whipple's disease
Crohn's disease
HLA-B27 associated conditions



Infectious disorders
Toxoplasmosis
Tuberculosis
Syphilis
Herpes simplex
Herpes zoster
Acute retinal necrosis
Cytomegalovirus
Coccidiomycosis
Hepatitis
Amoebiasis
Candidiasis
Leptospirosis
Ricketsia
Brucellosis
Lyme disease
Human immunodeficiency virus
Toxocariasis



Ocular disorders
Birdshot retinochoroidopathy
Pars planitis
Eale's disease
Retinal arteriolitis
Behcet's sine systemic disease
Sympathetic ophthalmia




Classification of retinal vasculitis by involved vessel
Disease
Primary vessel involved
Polyarteritis nodosa
Muscular arteries
Granulomatosis with polyangiitis (Wegener's); giant cell arteritis
Medium to small arteries
Systemic lupus erythematosus
Small arteries
Whipple's disease
Capillaries
Behcet's disease; sarcoidosis; multiple sclerosis
Veins
Crohn's disease; relapsing polychondritis
Arteries and veins
HLA-B27 associated conditions, such as ankylosing spondylitis
Variable or no involvement